We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Monday, 13 May 2019, highlighting Roche data presented at the American Academy of Neurology (AAN) Annual Meeting (4-10 May 2019) in Philadelphia, United States.
Agenda: Welcome
Karl Mahler, Head of Investor Relations
Overview of Roche key data at AAN covering new analysis from Ocrevus, satralizumab SakuraSky phase III data, risdiplam one year part I FIREFISH and SUNFISH data and dose selection data for the phase III study in Huntington's Disease
Paulo Fontoura, Global Head Neuroscience and Rare Diseases Clinical Development
Roche Neuroscience and Rare Disease franchise update
Karsten Jung, Therapeutic Area Head Neuroscience and Rare Diseases
Q&A
We would like to invite all interested parties to dial in as outlined below:
17:00 - 18:15 CEST / 16:00 - 17:15 BST
11:00 am - 12:15 pm EDT / 8:00 - 9:15 am PDT
Live audio webcast and conference call will start with presentations followed by a Q&A session (live access to the speakers).
The live audio webcast can be accessed via ir.roche.com.
In order to receive your personal dial-in details and expedite your access to the conference call, please pre-register under this link.
If you have not pre-registered, please find the dial-in numbers below, we recommend you to dial in to the conference 10-15 min prior to the scheduled start.
+41 (0) 58 310 5000 (Europe and ROW)
+44 (0) 207 107 0613 (UK)
+1 (1) 631 570 5613 (USA Toll Free)
Presentation slides will be posted on the Roche IR website click here.
A replay of the webcast will be available via ir.roche.com. |
